# Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

> **NCT06059326** · PHASE2 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** HSK7653 10 mg
- **DRUG:** HSK7653 25 mg
- **DRUG:** HSK7653 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06059326
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-22
- **Primary completion:** 2019-11-05
- **Final completion:** 2019-11-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059326, "Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06059326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*